ClinicalTrials.gg
RecruitingNCT07259681MicrOGineToxUpdated Sep 23, 2026

Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)

An observational study in Pelvic Toxicity, Radiation Toxicity and Chemotherapy Toxicity, sponsored by Bernardino Clavo, MD, PhD. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Bernardino Clavo, MD, PhD · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
38
Ages
18 Years and older
Sex
Female
01

Study summary

Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.

Read the detailed description

Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.

02

Conditions studied

  • Pelvic Toxicity
  • Radiation Toxicity
  • Chemotherapy Toxicity
  • Gynecological Tumors
  • Radiation Proctitis
  • Radiation Cystitis
  • Vaginal Mucositis
  • Vulvar Mucositis
  • Quality of Life
  • Dysbiosis

Keywords

  • Gut microbiota
  • Ozone
  • Ozone therapy
  • Gynecological tumors
  • Radiotherapy
  • Chemotherapy
  • Side effects
  • Actinic proctitis
  • Actinic cystitis
  • Quality of life
  • Dysbiosis
03

In context

Radiation Injuries

328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.

This study's planned enrollment of 38 is below the median of 130 across 96 observational studies indexed under Radiation Injuries.

Browse Radiation Injuries studies →

Lead sponsor

Bernardino Clavo, MD, PhD is the lead sponsor of 10 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with gynecological tumors treated with RT and/or CT with or without chronic pelvic toxicity (TPIRQT).

Eligibility criteria

Inclusion Criteria for all patients (Cases and Controls):

  1. Adult women (>=18 years).
  2. Diagnosed with gynecological tumors (any location and stage).
  3. Previously treated with radiotherapy and/or chemotherapy.
  4. Must accept and sign the specific for this study.

    Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases):

  5. Must present chronic TPIRQT with >= 3 months of duration after habitual symptomatic treatment.
  6. Must have a toxicity Grade of 2 (moderate symptoms, limiting instrumental ADL) or higher, according to the v.5.0 scale.

Exclusion Criteria for all patients (Cases and Controls):

  1. Not meeting all inclusion criteria.
  2. Presence of active inflammatory bowel disease (e.g., Crohn's Disease, Ulcerative Colitis) or a history of major gastrointestinal resection (excluding appendectomy) that could significantly alter gut anatomy and microbiota.
  3. Any uncontrolled intercurrent illness or psychiatric condition that, in the investigator's opinion, would limit compliance with study requirements or interfere with the interpretation of results.
  4. Unwillingness or inability to provide written informed consent for study participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
38 participants (estimated)
Target follow-up
4 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • TPIRQT Group (Cases)

    Patients with gynecological tumors treated with RT and/or CT who develop chronic pelvic toxicity (TPIRQT) and are referred for compassionate-use rectal ozone therapy at the Chronic Pain Unit. Samples and data will be collected before and after ozone therapy

  • Control Group

    pelvic toxicity (TPIRQT). This group will be matched by age (± 5 years) and primary tumor location. Samples and data will be collected once during a follow-up visit.

06

What researchers measure

Primary outcomes

  1. Comparison of gut microbiome profile (composition and diversity) between TPIRQT and Control groups

    Gut microbiome composition and diversity (from a single sample) in control patients will be compared to the baseline profile of patients with TPIRQT.

    Time frame: Baseline (single time point for controls, pre-ozone for cases)

  2. Change in gut microbiome profile (composition and diversity) in patients with TPIRQT after rectal ozone therapy.

    Gut microbiome composition and diversity will be analyzed from stool samples using 16S ribosomal RNA gene sequencing.

    Time frame: Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)

  3. Correlation of gut microbiome profile with grade of pelvic toxicity.

    Toxicity will be assessed using: i) the CTCAE v.5.0 scale from the NCI , and ii) the EORTC QLQ-CX24 questionnaire. This will be evaluated for its relationship to microbiome data.

    Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

Secondary outcomes

  1. Correlation of gut microbiome profile with health-related quality of life (HRQoL).

    HRQoL will be assessed using: i) the EQ-5D-5L questionnaire, and ii) the EORTC QLQ-C30 questionnaire. This will be evaluated for its relationship to microbiome data.

    Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

  2. Correlation of gut microbiome profile with anxiety and depression levels.

    Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). This will be evaluated for its relationship to microbiome data.

    Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

  3. Correlation of gut microbiome profile with biochemical markers of oxidative stress and inflammation.

    Serum samples will be collected to analyze biochemical parameters of oxidative stress and inflammation and their potential relationship with gut microbiome composition.

    Time frame: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).

07

Study locations

2 of 2 sites recruiting
  • Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
    Las Palmas de Gran Canaria, Las Palmas 35019, Spain
    Recruiting
  • Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias - Universidad de La Laguna
    San Cristóbal de La Laguna, Tenerife 38296, Spain
    Recruiting
08

References and documents

Publications

  • Clavo B, Canovas-Molina A, Ramallo-Farina Y, Federico M, Rodriguez-Abreu D, Galvan S, Ribeiro I, Marques da Silva SC, Navarro M, Gonzalez-Beltran D, Diaz-Garrido JA, Cazorla-Rivero S, Rodriguez-Esparragon F, Serrano-Aguilar P. Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors. Int J Environ Res Public Health. 2023 Jan 13;20(2):1479. doi: 10.3390/ijerph20021479. PubMed 36674232 ↗
  • Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Long-Term Results with Adjuvant Ozone Therapy in the Management of Chronic Pelvic Pain Secondary to Cancer Treatment. Pain Med. 2021 Sep 8;22(9):2138-2141. doi: 10.1093/pm/pnaa459. No abstract available. PubMed 33738491 ↗
  • Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Ozone Therapy in Refractory Pelvic Pain Syndromes Secondary to Cancer Treatment: A New Approach Warranting Exploration. J Palliat Med. 2021 Jan;24(1):97-102. doi: 10.1089/jpm.2019.0597. Epub 2020 May 5. PubMed 32379556 ↗
  • Clavo B, Santana-Rodriguez N, Llontop P, Gutierrez D, Ceballos D, Mendez C, Rovira G, Suarez G, Rey-Baltar D, Garcia-Cabrera L, Martinez-Sanchez G, Fiuza D. Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients. Evid Based Complement Alternat Med. 2015;2015:480369. doi: 10.1155/2015/480369. Epub 2015 Aug 18. PubMed 26357522 ↗
  • Clavo B, Ceballos D, Gutierrez D, Rovira G, Suarez G, Lopez L, Pinar B, Cabezon A, Morales V, Oliva E, Fiuza D, Santana-Rodriguez N. Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy. J Pain Symptom Manage. 2013 Jul;46(1):106-12. doi: 10.1016/j.jpainsymman.2012.06.017. Epub 2012 Oct 26. PubMed 23102757 ↗
  • Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, Su Y, Cheng T, Wang J. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One. 2015 May 8;10(5):e0126312. doi: 10.1371/journal.pone.0126312. eCollection 2015. PubMed 25955845 ↗
  • Wang L, Wang X, Zhang G, Ma Y, Zhang Q, Li Z, Ran J, Hou X, Geng Y, Yang Z, Feng S, Li C, Zhao X. The impact of pelvic radiotherapy on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review. Radiat Oncol. 2021 Sep 25;16(1):187. doi: 10.1186/s13014-021-01899-y. PubMed 34563216 ↗
  • Li L, Yang Z, Yi Y, Song Y, Zhang W. Gut microbiota and radiation-induced injury: mechanistic insights and microbial therapies. Gut Microbes. 2025 Dec;17(1):2528429. doi: 10.1080/19490976.2025.2528429. Epub 2025 Jul 6. PubMed 40618373 ↗
  • Ma CY, Zhao J, Xu XT, He XL, Qin SB, Zhou JY. Predictive biomarkers in the gut microbiome and metabolome for severe acute radiation enteritis in cervical cancer radiotherapy. Discov Oncol. 2025 Jul 1;16(1):1220. doi: 10.1007/s12672-025-03077-y. PubMed 40591053 ↗

Individual participant data

Plan to share: Yes — It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification Data will be available after publication, ending 36 months following article publication. They will be available for investigators whose proposed use of the data has been apd by an independent review committee identified for this purpose.

Time frame: Data will be available after publication, ending 36 months following article publication.

Access criteria: They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.

Of 55 observational studies under Radiation Injuries, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 189. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 2, 2025
StartActual
Jan 15, 2026
Primary completionEst.
Jan 15, 2028
CompletionEst.
Mar 31, 2028
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259681
Lead sponsor
Bernardino Clavo, MD, PhD
Collaborators
Hospital Universitario de Gran Canaria Doctor Negrín, Complejo Hospitalario Universitario Insular Materno Infantil, Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Centers for International Business Education and Research
Responsible party
Bernardino Clavo, MD, PhD (Principal Investigator, Research Unit Director, Hospital Universitario de Gran Canaria Doctor Negrín) — Sponsor-investigator
First posted
Dec 2, 2025
Start date
Jan 15, 2026
Primary completion
Jan 15, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Bernardino Clavo, MD, PhD
Contact
bernardinoclavo@gmail.com
34928449278
Francisco Rodríguez-Esparragón, BSc, PhD
Contact
afrodesp@gmail.com
34928449288
Bernardino Clavo, MD, PhD
study chair · Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
Jacob Lorenzo-Morales, Prof
principal investigator · Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias, Universidad La Laguna
Francisco Rodríguez-Esparragón, BSc, PhD
principal investigator · Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion